Get the Stockscreener App
35.64
0.62%
0.22
After Hours:
35.71
0.07
+0.20%
Royalty Pharma Plc stock is traded at $35.64, with a volume of 9.03M.
It is up +0.62% in the last 24 hours and down -1.95% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$35.42
Open:
$35.58
24h Volume:
9.03M
Relative Volume:
2.53
Market Cap:
$15.41B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
15.50
EPS:
2.3
Net Cash Flow:
$827.02M
1W Performance:
-1.49%
1M Performance:
-1.95%
6M Performance:
+7.93%
1Y Performance:
+26.20%
1-Day Range:
$35.46
$35.84
1-Week Range:
$34.84
$36.94
52-Week Range:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
35.64 | 15.31B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma’s $2 Billion Debt Offering Could Be a Game Changer for RPRX - simplywall.st
TD Cowen Maintains a Buy on Royalty Pharma (RPRX) - uk.finance.yahoo.com
Strs Ohio Invests $1.89 Million in Royalty Pharma PLC $RPRX - MarketBeat
Syndax, Royalty Pharma enter into $350M royalty funding deal - MSN
Empowered Funds LLC Buys New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Completes $2 Billion Senior Notes Offering - TipRanks
Royalty pharma to buy its external manager, announces $3B share buyback - MSN
Gainers Report: Will Royalty Pharma plc outperform the market in YEARMarket Sentiment Summary & Stock Timing and Entry Methods - خودرو بانک
Royalty Pharma stock price target raised to $38 from $37 at UBS - Investing.com UK
Pullback Watch: Is Royalty Pharma plc stock undervalued right nowWeekly Trade Analysis & Consistent Return Investment Signals - خودرو بانک
Royalty Pharma (RPRX) PT Raised to $38 at UBS, But Firm on Sidelines Due to Structural Issues - StreetInsider
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts - Yahoo Finance
Royalty Pharma Plc's (NASDAQ:RPRX) Prospects Need A Boost To Lift Shares - 富途牛牛
Aug Chart Watch: Is Royalty Pharma plc stock technically oversoldTrade Risk Assessment & Community Verified Trade Alerts - خودرو بانک
Pacific Capital Partners Ltd Decreases Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Petrus Trust Company LTA Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment - Yahoo Finance
Signal Recap: Will Royalty Pharma plc be affected by tariffs2025 Earnings Surprises & AI Powered Market Entry Strategies - خودرو بانک
USS Investment Management Ltd Sells 42,500 Shares of Royalty Pharma PLC $RPRX - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Grows Holdings in Royalty Pharma PLC $RPRX - MarketBeat
EP Wealth Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Royalty Pharma (RPRX): Evaluating Valuation After $2 Billion Debt Offering and New Capital Moves - Sahm
Uniplan Investment Counsel Inc. Purchases 11,904 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Stake Lessened by Baird Financial Group Inc. - MarketBeat
TD Cowen reiterates Buy rating on Royalty Pharma stock, citing strong metrics - Investing.com Nigeria
Royalty Pharma: Investor Day Upside (NASDAQ:RPRX) - Seeking Alpha
TD Cowen Reiterates Buy Rating on Royalty Pharma (RPRX) - StreetInsider
Alliancebernstein L.P. Purchases 86,873 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation - MarketScreener
Volatility clustering patterns for Royalty Pharma plcCEO Change & AI Enhanced Market Trend Forecasts - Newser
Why Royalty Pharma plc is moving todayMarket Risk Report & Smart Allocation Stock Tips - Newser
Punch & Associates Investment Management Inc. Purchases 101,390 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Transcript : Royalty Pharma plcAnalyst/Investor Day - MarketScreener
Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program - Insider Monkey
Royalty Pharma prices $2B senior unsecured notes - MSN
Royalty Pharma Expects At Least Mid-teens Average Annual Total Shareholder Return Over 2025-2030. - Nasdaq
Royalty Pharma : Investor Day Presentation - MarketScreener
Royalty Pharma : Role of Royalties in Funding Biopharma Innovation - MarketScreener
Royalty Pharma targets mid-teens annual shareholder return over next 5 years - MarketScreener
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation - MarketScreener
Royalty Pharma PLC $RPRX Stock Position Lifted by AQR Capital Management LLC - MarketBeat
Nomura Holdings Inc. Buys New Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma and Deloitte Release Landmark Report on Biopharma Royalty Market Insights and Trends - Quiver Quantitative
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market - MarketScreener
87% of Pharma Leaders Embrace Royalty Funding: Royalty Pharma's Groundbreaking Industry Study Reveals Shift - Stock Titan
Amundi Sells 1,316,620 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Eventide Asset Management LLC Acquires 56,419 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cutter Capital Management LP Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
Panagora Asset Management Inc. Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma’s $2 Billion Debt Raise Could Be a Game Changer for RPRX - simplywall.st
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.07%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):